These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 14513254)

  • 41. Rosacea fulminans associated with pegylated interferon alpha-2B and ribavirin therapy.
    Jensen SL; Holmes R
    J Drugs Dermatol; 2003 Oct; 2(5):554-6. PubMed ID: 14558405
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection.
    Kartal ED; Alpat SN; Ozgunes I; Usluer G
    Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):817-20. PubMed ID: 17700271
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dimorphic exanthema manifested as reticular maculopapular exanthema and erythema multiforme major associated with pyrazolon derivatives.
    Chen W; Hsieh FS
    Eur J Dermatol; 2002; 12(5):488-90. PubMed ID: 12370143
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Intertriginous rash caused by pegylated liposomal doxorubicin].
    Monteagudo B; Afonso-Afonso FJ; Cabanillas M; Used-Aznar MM
    Actas Dermosifiliogr; 2009 Apr; 100(3):241-2. PubMed ID: 19457315
    [No Abstract]   [Full Text] [Related]  

  • 45. Efonidipine-Induced Exanthematic Drug Eruption and Literature Review.
    Davis S; Raju AR; Thomas E; Cherian JJ
    J Cardiovasc Pharmacol; 2019 Jun; 73(6):394-396. PubMed ID: 31162248
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cutaneous necrosis complicating the injection of pegylated interferon alpha-2b in a patient with chronic hepatitis C.
    Rosina P; Girolomoni G
    Acta Dermatovenerol Croat; 2008; 16(1):35-7. PubMed ID: 18358108
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Meyerson's phenomenon induced by interferon-alfa plus ribavirin in hepatitis C infection.
    Girard C; Bessis D; Blatìre V; Guilhou JJ; Guillot B
    Br J Dermatol; 2005 Jan; 152(1):182-3. PubMed ID: 15656829
    [No Abstract]   [Full Text] [Related]  

  • 48. A longitudinal cohort study of mucocutaneous drug eruptions during interferon and ribavirin treatment of hepatitis C.
    Tavakoli-Tabasi S; Bagree A
    J Clin Gastroenterol; 2012 Feb; 46(2):162-7. PubMed ID: 21814144
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Exanthema caused by ingestion of potassium p-aminobenzoate (POTABA-Glenwood(®) ).
    Meyer-Hoffert U; Jensen JM; Brasch J
    Contact Dermatitis; 2013 Jun; 68(6):381-2. PubMed ID: 23692041
    [No Abstract]   [Full Text] [Related]  

  • 50. Generalized interstitial granuloma annulare induced by pegylated interferon-alpha.
    Kluger N; Moguelet P; Chaslin-Ferbus D; Khosrotherani K; Aractingi S
    Dermatology; 2006; 213(3):248-9. PubMed ID: 17033180
    [No Abstract]   [Full Text] [Related]  

  • 51. [Fatal Outcome for subcutaneous administration of Pegylated IFN alpha 2b in a man with Chronic C hepatitis under treatment with traditional bitherapy].
    Domínguez Gozalo A; Hidalgo Correas FJ; García Benayas E; García Díaz B
    Farm Hosp; 2015 May; 39(3):186-8. PubMed ID: 26005896
    [No Abstract]   [Full Text] [Related]  

  • 52. Symmetrical drug-related intertriginous and flexural exanthema caused by valacyclovir.
    Daito J; Hanada K; Katoh N; Katoh S; Sakamoto K; Asai J; Takenaka H; Kishimoto S
    Dermatology; 2009; 218(1):60-2. PubMed ID: 18974630
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Case of rifampicin-induced acute generalized exanthematous pustulosis.
    Azad A; Connelly N
    Intern Med J; 2006 Sep; 36(9):619-20. PubMed ID: 16911558
    [No Abstract]   [Full Text] [Related]  

  • 54. Elevated serum levels of interleukins 5, 6, and 10 in a patient with drug-induced exanthem caused by systemic corticosteroids.
    Yawalkar N; Hari Y; Helbing A; von Greyerz S; Kappeler A; Baathen LR; Pichler WJ
    J Am Acad Dermatol; 1998 Nov; 39(5 Pt 1):790-3. PubMed ID: 9810897
    [No Abstract]   [Full Text] [Related]  

  • 55. [Sarcoidosis induced by therapy with pegylated interferon alfa-2a].
    Bruch-Gerharz D; Reifenberger J
    Hautarzt; 2006 Apr; 57(4):317-35. PubMed ID: 16523277
    [No Abstract]   [Full Text] [Related]  

  • 56. Drug-induced hypersensitivity syndrome induced by clindamycin.
    Nakamura Y; Watamatsu K; Muto M
    Acta Derm Venereol; 2013 Jan; 93(1):83-4. PubMed ID: 22855006
    [No Abstract]   [Full Text] [Related]  

  • 57. Eczematous Drug Eruptions.
    Blum AE; Burgin S
    Am J Clin Dermatol; 2021 May; 22(3):349-366. PubMed ID: 33587283
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ambroxol-induced systemic contact dermatitis confirmed by positive patch test.
    Monzón S; Del Mar Garcés M; Lezaun A; Fraj J; Asunción Dominguez M; Colás C
    Allergol Immunopathol (Madr); 2009; 37(3):167-8. PubMed ID: 19769851
    [No Abstract]   [Full Text] [Related]  

  • 59. Cutaneous necrosis after injection of polyethylene glycol-modified interferon alfa.
    Dalmau J; Pimentel CL; Puig L; Peramiquel L; Roé E; Alomar A
    J Am Acad Dermatol; 2005 Jul; 53(1):62-6. PubMed ID: 15965422
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Thrombotic thrombocytopenic purpura with fatal outcome in a patient with chronic hepatitis C treated with pegylated interferon-a/2b.
    Deutsch M; Manesis EK; Hadziyannis E; Vassilopoulos D; Archimandritis AJ
    Scand J Gastroenterol; 2007 Mar; 42(3):408-9. PubMed ID: 17354123
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.